Survey of drug-resistant tuberculosis in Northwestern Russia from 1984 through 1994

  • M. K. Viljanen
  • B. I. Vyshnevskiy
  • T. F. Otten
  • E. Vyshnevskaya
  • M. Marjamäki
  • H. Soini
  • P. J. Laippala
  • A. V. Vasilyef


The morbidity, mortality, and relapse rates of tuberculosis have increased in the Russian Federation since 1991. Increased drug resistance may be one reason for the weakened efficacy of local tuberculosis treatments. Laboratory data on tuberculosis resistance were collected from a survey area that included two republics and seven other administrative regions (oblasts) with a total population of more than 14 million. Susceptibility data from 1991 through 1994 were available from all nine regions; data on resistance to individual drugs and data from 1984 through 1994 were available from the Leningrad region and the city of St. Petersburg. From 1991 through 1994, the annual notification rate of tuberculosis increased in the survey area by 53.7% (from 25.1 to 38.6 cases per 100000 inhabitants), tuberculosis mortality doubled (from 4.4 to 9.2 deaths per 100000), and primary resistance to at least one drug increased from 17% (95% CI, 14.9–19.9) to 24% (95% CI, 22.2.–25.8). The prevalence of primary resistance to at least isoniazid and rifampin (multidrug resistance) was 5.1% in the Leningrad region in 1992 through 1994. The proportion of pulmonary isolates with secondary multidrug resistance increased from 21.6% (95% CI 7.9–25.3%) in the period 1984–1994 to 33% (95% CI 29.7–36.3%) in 1989–1994. Even if these figures are biased upwards because of selection, it can be concluded that secondary resistance to tuberculosis drugs was already prevalent in northwestern Russia ten years ago. Since then, a distinct shift towards multidrug resistance has occurred. The lower prevalence of primary multidrug resistance raises hopes that the resistance problem can be controlled with properly designed and monitored therapeutic measures.

Key words

Tuberculosis Resistance Epidemiology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Centers for Disease Control: Tuberculosis morbidity — United States, 1992. Morbidity and Mortality Weekly Report (1993) 42:696–704.Google Scholar
  2. 2.
    Raviglione MC, Sudre P, Riedel HL, Spinaci S, Kochi A: Secular trends of tuberculosis in western Europe. Bulletin of the World Health Organization (1993) 71:297–306.PubMedGoogle Scholar
  3. 3.
    Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A: Tuberculosis trends in eastern Europe and the former USSR. Tubercle and Lung Disease (1994) 75:400–416.PubMedGoogle Scholar
  4. 4.
    World Health Organization: Tuberculosis trends in central and eastern Europe and countries of the former USSR. Weekly Epidemiological Record (1995) 70:21–22.Google Scholar
  5. 5.
    Drobniewski F, Tayler E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C: Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment. Tubercle and Lung Disease (1966) 77:199–206.Google Scholar
  6. 6.
    Lavy A, Mates A: A 10 year survey onMycobacterium tuberculosis isolates in Israel and their drug resistance. Israel Journal of Medical Sciences (1994) 30:805–810.PubMedGoogle Scholar
  7. 7.
    Wayne LG, Krasnow I: Preparation of tuberculosis susceptibility testing mediums by impregnated discs. American Journal of Pathology (1966) 45:769–771.Google Scholar
  8. 8.
    Gardner MJ, Altman DG: Statistics with confidence (book). British Medical Journal. London, 1989.Google Scholar
  9. 9.
    Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. New England Journal of Medicine (1993) 328:521–526.PubMedGoogle Scholar
  10. 10.
    Weltman AC, Rose DN: Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Archives of Internal Medicine (1994) 154:2161–2167.PubMedGoogle Scholar
  11. 11.
    Borchardt J, Kirsten D, Jorres R, Kroeger C, Magnussen H: Drug-resistant tuberculosis in northern Germany: a retrospective hospital-based study of 1,055 patients from 1984 until 1993. European Respiratory Journal (1995) 8:1076–1083.PubMedGoogle Scholar
  12. 12.
    Bouvet E: Multiresistant tuberculosis. Presse Medicale (1996) 25:393–398.Google Scholar
  13. 13.
    Hoffner SE:Mycobacterium tuberculosis; some data from Sweden, Estonia and Ethiopia. Scandinavian Journal of Infectious Diseases (1995) 98:17–18.PubMedGoogle Scholar
  14. 14.
    Schaberg T, Gloger G, Reichert B, Mauch H, Lode H: Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987–1993. European Respiratory Journal (1995) 8:278–284.PubMedGoogle Scholar
  15. 15.
    Tala E, Viljanen MK: Mycobacterial infections in Finland. Scandinavian Journal of Infectious Diseases (1995) 98:7–8.PubMedGoogle Scholar
  16. 16.
    Barnes PF, Elhajj H, Preston-Martin S, Cave MD, Jones BE, Otaya M, Pogoda J, Eisenach KD: Transmission of tuberculosis among the urban homeless. Journal of the American Medical Association (1996) 275:305–307.PubMedGoogle Scholar
  17. 17.
    Friedman LN, Sullivan GM, Bevilaqua RP, Loscos R: Tuberculosis screening in alcoholics and drug addicts. American Review of Respiratory Disease (1987) 136:1188–1192.PubMedGoogle Scholar
  18. 18.
    Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R: Drug resistant tuberculosis among the homeless in New York City. New York State Journal of Medicine (1990) 90:351–355.PubMedGoogle Scholar
  19. 19.
    Brudney K, Dobkin J: Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. American Review of Respiratory Disease (1991) 144:745–749.PubMedGoogle Scholar
  20. 20.
    Morris JT, McAllister CK: Homeless individuals and drug-resistant tuberculosis in south Texas. Chest (1992) 102:802–804.PubMedGoogle Scholar
  21. 21.
    Friedman LN, Williams MT, Singh TP, Frieden TR: Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. New England Journal of Medicine (1996) 334:828–833.PubMedGoogle Scholar
  22. 22.
    Drobniewski F, Tayler E, Ignatenko N, Paul J, Connolly M, Nye P, Lyagoshina T, Besse C: Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment. Tubercle and Lung Disease (1966) 77:297–301.Google Scholar
  23. 23.
    Weis SE, Slocum PC, Biais FX, King B, Nunn M, Matney GB, Comez E, Foresman BH: The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. New England Journal of Medicine (1994) 330:1179–1184.PubMedGoogle Scholar
  24. 24.
    Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN: Comprehensive tuberculosis control for patients at high risk for noncompliance. American Journal of Respiratory and Critical Care Medicine (1995) 151:1486–1490.PubMedGoogle Scholar
  25. 25.
    Chaulk CP, Moorerice K, Rizzo R, Chaisson RE: Eleven years of community-based directly observed therapy for tuberculosis. Journal of the American Medical Association (1995) 274:945–951.PubMedGoogle Scholar
  26. 26.
    Zhao FZ, Murray C, Spinaci S, Styblo K, Broekmans J, Zou JQ, Dai YS, Chi YH, Du X, Cao JP, Chen YL, Li LM, Liu CJ, Liu HQ, Lu Q, Tang DR, Wang PF, Wang ZH, Wu PE, Zhang FD, Zhang FS, Zhu GL: Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet (1996) 347:358–362.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • M. K. Viljanen
    • 1
  • B. I. Vyshnevskiy
    • 2
  • T. F. Otten
    • 2
  • E. Vyshnevskaya
    • 2
  • M. Marjamäki
    • 1
  • H. Soini
    • 1
  • P. J. Laippala
    • 3
  • A. V. Vasilyef
    • 2
  1. 1.Department in TurkuNational Public Health InstituteTurkuFinland
  2. 2.Research Institution of PhthisiopulmonologySt. PetersburgRussia
  3. 3.Tampere School of Public HealthUniversity of Tampere and Tampere University HospitalTampereFinland

Personalised recommendations